Form 4 for XFOR X4 Pharmaceuticals, Inc
Accepted 2022-03-01 00:00:00 ET · period of report 2022-03-01 · accession 0001628280-22-004518 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-01 | 2022-03-01 | XFOR | DiBiase Mary | COO | A - Grant | $0.00 | +105.0K | 182.9K | +135% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-01 | A | A | 105,000 | $0.00 | 182,899 | D | — | — | (F1) Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. (F2) Of the shares of common stock reported, 177,748 shares represent unvested restricted stock units. |